Advances in antiarrhythmic drug treatment of atrial fibrillation: Where do we stand now?

被引：30

作者：

Camm, AJ ^{[1
]}

Savelieva, I ^{[1
]}

机构：

[1] St George Hosp, Sch Med, London SW17 0RE, England

来源：

HEART RHYTHM | 2004年 / 1卷 / 02期

关键词：

D O I：

10.1016/j.hrthm.2004.02.023

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：244 / 246

页数：3

共 17 条

[1]

Billman George E, 2003, Curr Opin Investig Drugs, V4, P352

[2] Tarantula peptide inhibits atrial fibrillation - A peptide from spider venom can prevent the heartbeat from losing its rhythm. [J].

Bode, F ;

Sachs, F ;

Franz, MR .

NATURE, 2001, 409 (6816) :35-36

[3] Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation [J].

Connolly, SJ ;

Schnell, DJ ;

Page, RL ;

Wilkinson, WE ;

Marcello, SR ;

Pritchett, ELC .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (09) :974-979

[4] MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL [J].

ECHT, DS ;

LIEBSON, PR ;

MITCHELL, LB ;

PETERS, RW ;

OBIASMANNO, D ;

BARKER, AH ;

ARENSBERG, D ;

BAKER, A ;

FRIEDMAN, L ;

GREENE, HL ;

HUTHER, ML ;

RICHARDSON, DW .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) :781-788

[5] Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study [J].

Go, AS ;

Hylek, EM ;

Phillips, KA ;

Chang, YC ;

Henault, LE ;

Selby, JV ;

Singer, DE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18) :2370-2375

[6] Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation [J].

Goette, A ;

Staack, T ;

Röcken, C ;

Arndt, M ;

Geller, JC ;

Huth, C ;

Ansorge, S ;

Klein, HU ;

Lendeckel, U .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (06) :1669-1677

[7] Rhythm or rate control in atrial fibrillation - Pharmacological intervention in atrial fibrillation (PIAF): a randomised trial [J].

Hohnloser, SH ;

Kuck, KH ;

Lilienthal, J .

LANCET, 2000, 356 (9244) :1789-1794

[8] Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation a prospective and randomized study [J].

Madrid, AH ;

Bueno, MG ;

Rebollo, JMG ;

Marín, I ;

Peña, G ;

Bernal, E ;

Rodriguez, A ;

Cano, L ;

Cano, JM ;

Cabeza, P ;

Moro, C .

CIRCULATION, 2002, 106 (03) :331-336

[9] Increase in gap junction conductance by an antiarrhythmic peptide [J].

Muller, A ;

Gottwald, M ;

Tudyka, T ;

Linke, W ;

Klaus, W ;

Dhein, S .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 327 (01) :65-72

[10] Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction [J].

Pedersen, OD ;

Bagger, H ;

Kober, L ;

Torp-Pedersen, C .

CIRCULATION, 1999, 100 (04) :376-380

← 1 2 →